Depressive disorder
Conditions
Interventions
Normal dose group:Paroxetine therapeutic dose: 25mg qd
high dose group:Paroxetine therapeutic dose: 50mg qd
dose adjustment group:Paroxetine therapeutic dose: changed in treatment
Sponsors
Department of Pharmacy, ZhongDa Hospital, Southeast University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. During the treatment period, the subjects received TDM monitoring of paroxetine, and the medication compliance was good. After the first diagnosis, they were followed up on schedule; 2. It meets the diagnostic criteria of depression in DSM-V; 3. 17 items of Hamilton Depression Scale (HAMD-17) >= 17 points, and the first item (depression) score >= 2; 4. 18-80 years old, regardless of gender; 5. The patient agreed and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Accompanied by serious or unstable physical diseases, nervous system diseases and other mental disorders; 2. Patients used fluoxetine 3 weeks before enrollment, other antidepressants 1 week before enrollment, and more than 2 antidepressants at the same time after enrollment; 3. Women of childbearing age who are lactating, pregnant or do not take reasonable contraceptive measures; 4. Those who failed to take SSRI and SNRI drugs in the past, and those who were allergic to paroxetine in the past; 5. According to the judgment of the researcher, the medicine cannot be taken according to the doctor's advice.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale-17; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Scale-17;Plasma concentration of paroxetine; | — |
Countries
China
Contacts
Public ContactLingjun Zhong
Department of Pharmacy, ZhongDa Hospital, Southeast University
Outcome results
None listed